HIF1A and peripheral arterial disease: Therapeutically, concurrent or sequential activation of both isoforms may produce synergistic benefits: HIF-1α–driven neovascular initiation coupled with HIF-2α–mediated vessel stabilization and erythropoietic support—thereby enhancing the efficacy and durability of angiogenic therapies for ischemic cardiovascular and peripheral arterial diseases.